SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

October 19, 2010 09:00 ET

Cleveland BioLabs Receives Notice of Patent Allowance From China for CBLB502

BUFFALO, NY--(Marketwire - October 19, 2010) -  Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it has received a notice of grant of patent for CBLB502 from the State Intellectual Property Office of the People's Republic of China. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502.

Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, noted, "We are pleased with the continued positive results of our patent examinations for CBLB502 and other compounds in several key jurisdictions around the world. We believe the grant of these patents emphasizes our completely novel approach to protection of healthy tissues from the impact of radiation and other acute stresses."

About CBLB502
CBLB502 is a bio-engineered derivative of a microbial protein that potentially reduces injury from acute stresses, such as radiation and chemotherapy, by mobilizing several natural cell protective mechanisms, including inhibition of programmed cell death (apoptosis), reduction of oxidative damage and induction of regeneration-promoting cytokines. 

CBLB502 is being developed by Cleveland BioLabs under the FDA's Animal Efficacy Rule to treat acute radiation syndrome (ARS) or radiation poisoning from exposure to radiation such as a nuclear or radiological weapon / dirty bomb, or from a nuclear accident. This approval pathway requires demonstration of efficacy in representative animal models and safety, pharmacokinetic, pharmacodynamic and biomarker testing in healthy human subjects. In July 2010, CBLB502 was granted fast track status from the FDA for reducing the risk of death following total body irradiation during or after radiation disaster. There is currently no FDA approved medical countermeasure to reduce the risk of death following total body irradiation during or after radiation disaster.

Evidence of CBLB502's mechanism of action and activity in animal models was published in Science Magazine in April 2008 (Science, 2008, vol. 320, pp. 226-230). Data from 50 healthy human subjects in an initial Phase I safety and tolerability study indicated that CBLB502 was well tolerated and that normalized biomarker results corresponded to previously demonstrated activity in animal models of ARS. Top line data from a second safety and tolerability study in 100 healthy subjects confirmed that administration of CBLB502 resulted in a rapid and potent cytokine response, similar to that seen in the prior clinical trial and in previously conducted non-human primate studies, and that CBLB502 was well tolerated.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.

These factors include, among others, the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company's need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company's R&D grants and contracts; the Company's failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company's ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439